Alzamend Neuro, Inc. — Form 8-K
Filed November 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Alzamend Neuro's AL001, a novel lithium salicylate formulation designed for improved brain delivery with reduced systemic toxicity, was evaluated in a small open-label pharmacological fMRI study at Massachusetts General Hospital (MGH). Six healthy participants completed baseline and post-treatment imaging after two-week dosing with AL001 or standard lithium carbonate; exploratory analyses showed descriptive differences in brain functional connectivity between AL001 and Li2CO3 conditions but no changes survived statistical correction, with authors noting preliminary findings warrant larger cohort investigation.
Why this rating
Early-stage preclinical neuroimaging data in tiny sample (n=6, only 4 on AL001); no statistically significant efficacy signals; preliminary proof-of-concept only. Modest de-risking but not commercial validation for $9.6M company.
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.